Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2970 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis is Associated with Heterotopic Ossification after Total Hip Arthroplasty
Mario Cedillo¹, Arielle Fein², Susan M. Goodman³, Rebecca Zhu⁴, Mark P. Figgie⁵, Michael Alexiades⁶, Jayme C. Burket⁷ and Lisa A. Mandl³, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Clinical Research, Hospital for Special Surgery, New York, NY, ⁵Orthopedics, Hospital for Special Surgery, New York, NY, ⁶Orthopaedics, Hospital for Special Surgery, New York, NY, ⁷Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: Heterotopic ossification (HO), the pathologic deposition of ectopic bone in soft tissues, is a feared complication of total hip arthroplasty (THA). HO is strongly…
Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Steven R Feldman¹, Yang Zhao², Lizheng Shi³, Jackie Lu² and MaryHelen Tran², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Tulane University, New Orleans, LA
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Trayton Mains¹ and Vikas Majithia², ¹University of Mississippi Medical Center, Jackson, MS, ²G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…
Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Dafna D. Gladman⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
Abstract Number: 1553 • 2013 ACR/ARHP Annual Meeting
Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PRO) on Health Related Quality of Life (HRQoL) are increasingly used to assess responsiveness after treatment. This study aimed to determine the…
Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée M. van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.